FIG. 6.
Combination therapy targeted against endogenous TAA treats systemic disease. Naïve pmel T cells (1 × 106) were adoptively transferred into C57BL/6 mice bearing two B16ova tumors that had been established on both flanks 7 days previously (eight mice/group). On the same day, tumors on the right flank were injected intratumorally with 5 × 108 PFU of VSV-GFP or VSV-hgp100 every other day for six injections. (A) Survival (tumor less than 1.0 cm in any diameter) or (B–E) growth of individual tumors is shown.